Patients with rheumatoid arthritis (RA) treated with 10mg twice daily doses of Xeljanz or Xeljanz XR (tofacitinib), were at an increased risk of blood clots in the lungs (pulmonary embolism) and death, according to a safety clinical trial. The Food and Drug Administration (FDA) has not approved this dosage of Xeljanz RA for patients with RA; only for patients with ulcerative colitis. This issue was discovered during a clinical trial Pfizer was required to conduct when the drug was first approved by the FDA in 2016. The trial was designed to evaluate the risk of heart-related events, cancer and infection ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.